ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1591

Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?

Lihi Eder1, Chandra Farrer2 and Dana Jerome3, 1Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 2Rheumatology, Women's College Hospital, Toronto, ON, Canada, 3University of Toronto, Women's College Hospital, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Enthesitis, Outcome measures, Psoriatic arthritis, spondylarthritis and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Enthesitis is a key feature in psoriatic arthritis (PsA) affecting approximately a third of the patients. Ultrasound improves the detection of enthesitis compared to clinical examination. However, there is little information about the construct validity of sonographic enthesitis scores in PsA. We aimed to evaluate the correlation between the severity of sonographic enthesitis and measures of disease activity in patients with early PsA.

Methods: Sixty-four patients with early PsA (duration <5 years) who were naïve to biologic medications, were enrolled. PsA disease activity was assessed in each of the key domains using validated measures of disease activity, laboratory markers of inflammation and patient reported outcomes. The severity of sonographic enthesitis was assessed in 14 entheseal sites using a modification of the Madrid Enthesitis Scoring Index (MASEI) with power Doppler scored on a scale of 0 to 3. We considered the total score of modified MASEI (mod-MASEI) and the total Doppler scores (mod-MASEI-Dop) as the outcomes of interest. Pearson correlation coefficients were calculated between sonographic enthesitis scores and measure of disease activity. Since sonographic enthesitis is confounded by aging and mechanical stress we used regression analysis to evaluate the association between disease related measures and sonographic enthesitis after adjusting for age, sex and BMI.

Results: The mean age was 46.6±13.7 (53.1% males) and mean disease duration was 1±1.3 years. Clinical enthesitis was found in 51.6% (≥1 tender entheseal site) and active sonographic enthesitis was found in 57.8% of the patients. A mild to moderate correlation was found between sonographic enthesitis and tender and swollen joint counts, damaged joint count, clinical enthesitis count, physician global assessment and health assessment questionnaire (HAQ) (Table 1). In multivariable analysis the following variable were associated with higher sonographic enthesitis score (Table 2): nail pitting (β 9.3, 95% confidence interval (CI) 1.7, 16.8), physician global assessment (β 1.9, 95% CI 0.3, 3.5), HAQ (β 9.7, 95% CI 3.9, 15.5), swollen joint count (β 1.3, 95% CI 0.6, 1.8) and tender joint count (β 1.2, 95% CI 0.6, 1.8).

Conclusion: The severity of sonographic enthesitis correlates with measures of disease activity, joint damage and patient function in early PsA. These findings suggest that sonographic enthesitis has construct validity and may be considered as a marker of severity in early PsA.


 

Table 1 – The correlation sonographic enthesitis and measures of PsA disease activity

 

Modified MASEI – Total

Modified MASEI – Doppler score

 

r

P value

N

r

P value

N

Swollen joint count

0.44

<0.001

64

0.36

0.004

64

Tender joint count

0.44

<0.001

64

0.34

0.005

64

Damaged joint count

0.31

0.01

64

0.25

0.05

64

Tender enthesitis count

0.25

0.048

64

0.16

0.20

64

Dactylitis count

0.03

0.83

64

-0.02

0.86

64

Nail pitting

0.36

0.004

64

0.24

0.05

64

Nail onycholysis

0.02

0.89

64

0

0.94

64

PASI

0.09

0.47

64

0.06

0.62

64

MD global assessment

0.36

0.003

64

0.28

0.02

64

CRP

0.12

0.35

60

0.05

0.70

60

ESR

0.25

0.06

60

0.08

0.56

60

HAQ

0.31

0.01

61

0.21

0.10

61

Pain score

0.04

0.75

62

0

0.99

62

PGA arthritis

0

0.99

61

-0.04

0.77

61

PGA psoriasis

0.03

0.82

62

0.06

0.66

62

FACIT

-0.10

0.46

55

0

0.99

55

DLQI

0.08

0.53

59

0

0.98

59

ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; DLQI: Dermatology Life Quality Index; FACIT: Fatigue Functional Assessment of Chronic Illness; HAQ: Health Assessment Questionnaire; MD: physician; PASI: psoriasis area and severity index; PGA: Patient Global Assessment

 

Table 2 – The Association Between total Modified-MASEI and PsA Disease Related Variables by Linear Regression Model (N=64)

 

Univariate

Age-, Sex- and BMI adjusted model

 

β (95% CI)

P value

β (95% CI)

P value

Duration of Morning stiffness (>30 minutes)

4.7 (-2.7, 12.1)

0.21

6.3 (-0.6, 13.2)

0.08

Inflammatory back pain (yes)

2.7 (-5.4, 10.8)

0.51

5.1 (-2.2, 12.4)

0.17

Nail lesions (yes)

1.6 (-5.9, 9.1)

0.67

0.3 (-6.7, 7.2)

0.94

Nail pitting (yes)

12.2 (4.4, 20)

0.002

9.3 (1.7, 16.8)

0.02

Nail Onycholysis (yes)

0.5 (-7.7, 8.8)

0.89

-0.04 (-7.6, 7.6)

0.99

PASI

0.3 (-0.4, 1.0)

0.46

0.2 (-0.5, 0.9)

0.55

Dactylitis (yes)

-4.7 (-14.6, 5.2)

0.35

-2.4 (-11.6, 6.8)

0.61

Physician global assessment (0-10)

2.6 (1.0, 4.3)

0.002

1.9 (0.3, 3.5)

0.02

CRP (mg/dL)

0.1 (-0.1, 0.4)

0.33

0.1 (-0.1, 0.4)

0.40

ESR (mm/hr)

0.3 (0, 0.6)

0.05

0.2 (-0.04, 0.5)

0.09

BASDAI

0.7 (-1.1, 2.4)

0.47

0.9 (-0.7, 2.4)

0.28

FACIT

-0.1 (-0.4, 0.2)

0.46

-0.1 (-0.4, 0.2)

0.55

DLQI

0.2 (-0.3, 0.6)

0.52

0 (-0.4, 0.4)

0.95

HAQ

8.2 (1.9, 14.4)

0.009

9.7 (3.9, 15.5)

0.001

Pain (0-10)

0.7 (-0.6, 2.1)

0.26

0.8 (-0.4, 2.0)

0.20

PGA arthritis (0-10)

0.4 (-0.8, 1.7)

0.48

0.6 (-0.6, 1.7)

0.34

PGA skin (0-10)

0.6 (-0.6, 1.7)

0.35

0.7 (-0.4, 1.8)

0.19

Dactylitis count (0-20)

-0.4 (-3.9, 3.1)

0.83

0.6 (-2.6, 3.9)

0.70

Damaged joint count (0-68)

2.3 (0.6, 4.1)

0.008

1.5 (-0.3, 3.2)

0.10

Enthesitis count (0-14)

2.7 (0.1, 5.2)

0.04

2.3 (-0.2, 4.7)

0.07

Swollen joint count (0-66)

1.7 (0.8, 2.5)

<0.0001

1.3 (0.4, 2.1)

0.003

Tender joint count (0-68)

1.4 (0.7, 2.0)

0.0001

1.2 (0.6, 1.8)

0.0002

Radiographic sacroiliitis (Yes)

0.3 (-9.4, 9.9)

0.96

4.3 (-4.6, 13.1)

0.34

BASDAI – Bath Ankylosing Spondylitis Disease Activity Index, CRP- C Reactive Protein, DLQI – Dermatology Life Quality Index, ESR – Erythrocyte Sedimentation Rate, FACIT – Functional Assessment of Chronic Illness Therapy, HAQ – Health Assessment questionnaire, PASI – psoriasis area and severity index, PGA – Patient Global Assessment

 


Disclosure: L. Eder, None; C. Farrer, None; D. Jerome, None.

To cite this abstract in AMA style:

Eder L, Farrer C, Jerome D. Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/is-enthesitis-a-marker-of-disease-severity-in-early-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-enthesitis-a-marker-of-disease-severity-in-early-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology